Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients

Transplant International

Volumn 18, Issue 3, 2005, Pages 289-295

  Capecchi, Pier Leopoldo ^a,b   Rechichi, Serena ^a   Lazzerini, Pietro Enea ^a   Collini, Andrea ^b   Guideri, Francesca ^a   Ruggieri, Giuliana ^b   Carmellini, Mario ^b   Laghi Pasini, Franco ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Adenosine; Cyclosporin; Kidney transplant; Rapamycin; Tacrolimus

Indexed keywords

ADENOSINE; ADENOSINE KINASE; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE NUCLEOTIDE; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FEMALE; HEART PROTECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; AGED; BLOOD; KIDNEY TRANSPLANTATION; MIDDLE AGED;

ADENOSINE; ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 20844442485     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.00036.x     Document Type: Article

References (49)

1. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999; 288: 653.
2. Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T. Protective effect of FK506 on ischemia/reperfusion myocardial damage in canine heart. J Cardiovasc Pharmacol 1993; 21: 448.
3. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced myocardial damage in isolated rat hearts. J Mol Cell Cardiol 1993; 25: 1461.
4. Kawano K, Kim YI, Kaketani K, Kobayashi M. The beneficial effect of cyclosporine on liver ischemia in rats. Transplantation 1989; 48: 759.
5. Weinbrenner C, Liu GS, Downey JM, Cohen MV. Cyclosporine A limits myocardial infarct size even when administered after the onset of ischemia. Cardiovasc Res 1998; 38: 676.
6. Minners J, van den Bos EJ, Yellon DM, Schwalb H, Opie LH, Sack MN. Dinitrophenol, cyclosporin A, and trimedazidine modulate preconditioning in the isolated rat heart: support for a mitochondrial role in cardioprotection. Cardiovasc Res 2000; 47: 68.
7. Thornton JD, Liu GS, Olsson RA, Downey JM. Intravenous pre-treatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992; 85: 659.
8. Liu GS, Richards AC, Olsson RA, Mullane K, Walsh RS, Downey JM. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994; 28: 1057.
9. Guieu R, Dussol B, Devaux C, et al. Interactions between cyclosporine A and adenosine in kidney transplant recipients. Kidney Int 1998; 53: 200.
10. Hwang K-K, Hall CS, Spielman WS, Sparks HV. FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase. Eur J Pharmacol 2001; 425: 85.
11. Spychala J, Mitchell BS. Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes. J Lab Clin Med 2002; 140: 84.
12. Averill LE, Stein RL, Kammer GM. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 1998; 115: 88.
13. Orrico A, Capecchi PL, De Magistris T, Nuti S, Laghi-Pasini F. Differential effect of adenosine on DNA synthesis in lymphoid and myeloid cell lines. Exp Hematol 1991; 19: 1003.
14. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastures SM, Vizi ES. Adenosine receptor agonist differentially regulate IL-1O, TNF-alpha and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996; 157: 4634.
15. Eigler A, Greten TF, Sinha B, Chaslberger C, Sullivan GW, Enderas S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumor necrosis factor synthesis. Scand J Immunol 1997; 45: 132.
16. Huang S, Apasov S, Koshiba M, Sitkovsky MV. Role of A2a extracellular adenosine receptor-mediated signalling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997; 90: 1600.
17. Link AA, Kino T, Worth K, et al. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000; 164: 436.
18. Hasko G, Kuhel DG, Chen JF, et al. Adenosine inhibits IL-12 and TNF-alpha production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000; 14: 2065.
19. Sitkovsky MV. Use of the A(2A) adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem Pharmacol 2003; 65: 493.
20. Fideu MD, Arce A, Miras-Portugal MT, Esquifino AI. Prolactin and cyclosporine modulate adenosine transporters and adenosine Al receptors in the rat brain. J Physiol Biochem 2000; 56: 83.
21. Capecchi PL, Blardi P, De Lalla A, et al. Pharmacokinetics and pharmacodynamics of neutrophil-associated ciprofloxacin in humans. Clin Pharmacol Ther 1995; 57: 446.
22. Pearson JD, Carleton JS, Gordon JL. Metabolism of adenine nucleotides by ectoenzymes of vascular endothelial and smooth-muscle cells in culture. J Biochem 1980; 190: 421.
23. Borst MM, Schrader J. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res 1991; 68: 797.
24. Lüthie J. Extracellular adenosine compounds, red blood cells and haemostasis: facts and hypotheses. Blutalkohol 1989; 59: 369.
25. Mills DCB, Robb IA, Roberts GCM. The release of nucleotides, 5-hydroxytryptamine and enzymes from human blood platelets, during aggregation. J Physiol (London) 1968; 150: 715.
26. Newby A. The pigeon heart 5'-nucleotidase responsible for ischaemia-induced adenosine formation. Biochem J 1988; 253: 123.
27. Achtemberg PW, de Tombe PP, Harmsen E, De Jong JW. Myocardial S-adenosylomocysteine hydrolase is important for adenosine production during normoxia. Biochem Biophys Acta 1985; 840: 393.
28. 14C into rabbit heart adenine nucleotides. Am J Physiol 1971; 220: 1242.
29. Achtemberg PW, Harmsen E, De Jong JW. Adenosine deaminase inhibition and myocardial purine release during normoxia and ischemia. Cardiovasc Res 1985; 19: 593.
30. Young JD, Jarvis SM. Nucleoside transport in animal cells. Biosci Rep 1983; 3: 309.
31. Kroll K, Schrader J, Piper HM, Henrich M. Release of adenosine and cyclic AMP from coronary endothelium in isolated guinea pig hearts: relation to coronary flow. Circ Res 1987; 60: 659.
32. Decking UKM, Schlieper G, Kroll K, Schrader J. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. Circ Res 1997; 81: 154.
33. Decking UK, Alves C, Spahr R, Schrader J. 2-Fluoroadenosine uptake by erythrocytes and endothelial cells studied by 19F-NMR. Am J Physiol 1994; 266: H1596.
34. Spychala J, Mitchell BS, Barankiewicz J. Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: changes in expression pattern of adenosine kinase, adenosine deaminase, and 5′-nucleotidase. J Immunol 1997; 158: 4947.
35. Van Belle H, Goossens F, Wynants J. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am J Physiol 1987; 21: H886.
36. Di Perri T, Laghi-Pasini F, Pecchi S, et al. In vivo and in vitro evidence of an adenosine-mediated mechanism of calcium entry blocker activities. Angiology 1989; 40: 190.
37. Edlund A, Siden A, Sollevi A. Evidence for an antiaggregatory effect of adenosine at physiological concentration and for its role in the action of dipyridamole. Thromb Res 1989; 45: 183.
38. Kroll K, Decking UKM, Dreikorn K, Schrader J. Rapid turnover of the AMP-adenosine metabolic cycle in the guinea pig heart. Circ Res 1993; 73: 846.
39. Berne RM. Cardiac nucleotides in hypoxia: possible role in regulation of coronary blood flow. Am J Physiol 1963; 204: 317.
40. Sollevi A. Cardiovascular effects of adenosine in man; possible clinical implications. Prog Neurobiol 1986; 27: 319.
41. 2) release by activated human neutrophils. Clin Immunol Immunopathol 1987; 42: 76.
42. Gruber TN. Increased adenosine concentration in blood flow from ischaemic myocardium by AICA riboside: effects on flow, granulocyte and injury. Circulation 1989; 80: 1400.
43. Firestein GS. Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 1996; 39: 371.
44. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 50: 527.
45. Picano E, Abbracchio MP. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res Bull 2000; 52: 75.
46. Wisniewski HG, Hua JC, Poppers DM, Naime D, Vilcek J, Cronstein BN. TNF/IL-1-inducibile protein TSG-6 potentiates plasmin inhibition by inter alpha inhibitor and exerts a strong anti-inflammatory effect in vivo. J Immunol 1996; 156: 1609.
47. Averill LE, Stein RL, Kammer GM. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 1988; 115: 88.
48. Varani K, Laghi-Pasini F, Camurri A, et al. Changes of peripheral adenosine receptors in chronic heart failure and cardiac transplantation. FASEB J 2003; 17: 280.
49. Murray BM, Churchill PC. Concentration dependency of the renal vascular and renin secretory responses to adenosine receptors agonists. J Pharmacol Exp Ther 1985; 231: 189.